IDNA
iShares Genomics Immunology and Healthcare ETF
IDNA seeks to track the investment results of an index composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology, and bioengineering.
Global
EQUITY
Rules-Based
MANAGEMENT STYLE
$ 192.0 M
ASSETS UNDER MGMT
47 bp
EXPENSES
Fund Basics
| Inception date | Jun 11, 2019 |
| Regulation | Open-Ended Fund |
| Fund Website | link... |
| Distributions | Annually |
| Currency | USD |
| Holdings Transparency | Full |
| Derivatives-based | No |
| Options available | Yes |
| Currency hedged | No |
| Fund of funds | No |
Top 10 Holdings
Complete list +
| MODERNA, INC. | 4.9 % |
| BAYER AG | 4.7 % |
| TWIST BIOSCIENCE CORP. | 4.5 % |
| REVOLUTION MEDICINES, INC. | 4.3 % |
| GENMAB A/S | 4.0 % |
| INCYTE CORP | 3.9 % |
| VERTEX PHARMACEUTICALS INC | 3.7 % |
| TAKEDA PHARMACEUTICAL CO LTD | 3.7 % |
| EXELIXIS INC | 3.7 % |
| REGENERON PHARMACEUTICALS | 3.6 % |
Constituent Breakdown
| Number of holdings | 52 |
| Herfindahl-Hirschman Index | 302 |
| Wgt avg mkt cap (mns) | $37,156 |
| Large cap (>$10bn) | 53.5% |
| Mid cap ($2-10bn) | 19.5% |
| Small cap (<$2bn) | 14.1% |
| Developed mkts. | 86.6% |
| Emerging mkts. | 0.5% |
Sector Breakdown
Country Exposure
 |
UNITED STATES | 55.0 % |
 |
GERMANY | 8.2 % |
 |
FRANCE | 7.2 % |
 |
JAPAN | 5.5 % |
 |
DENMARK | 4.0 % |
 |
BRITAIN | 3.4 % |
 |
CANADA | 1.7 % |
 |
SWITZERLAND | 1.6 % |
 |
CHINA | 0.5 % |
Historical Performance
Standardized Performance (as of 06/30/2026)
| YTD | 1 YR | 2 YR | 3 YR | 5 YR | 10 YR | 20 YR | Incep. | |
|---|---|---|---|---|---|---|---|---|
| Price Returns | 28.9% | 64.6% | 20.8% | 13.1% | -8.3% | -- | -- | 4.4% |
| Dividend Yield | 0.5% | 1.7% | 1.3% | 1.3% | 0.9% | -- | -- | 0.9% |
| Total Returns | 29.4% | 66.2% | 22.2% | 14.4% | -7.4% | -- | -- | 5.3% | Ann. Volatility | 26.5% | 25.1% | 25.0% | 25.1% | 28.5% | -- | -- | 29.5% |
Market Correlations
| versus... | Beta | R-squared |
| S&P 500 | 1.05 | 27% |
| MSCI EAFE | 1.00 | 38% |
| MSCI Emg Mkts | 0.50 | 21% |
Liquidity Measures
| Avg. volume (000) | 69 |
| ADV traded (mns) | $2 |
| Turnover | 1.2% |
| Avg. Bid/Ask (% of price) | 0.21% |
Technical Indicators
| 30d moving avg. (EMA) | $32.00 |
| Relative strength (RSI) | 61 |
| MACD/Signal | 1.25/1.14 |
| Bollinger Bands (Upper/Lower) | $36.12/$28.51 |
| Short interest (% of AUM) | 0.1% |
Distributions
Top Ten Comparable ETFs only shown here. For an extended list become an Individual or Professional subscriber. Start your FREE trial
Comparable ETFs Based on Overlap
| Ticker | Fund Name | Overlap vs. IDNA |
Expenses vs. IDNA |
ALTAR Score™ vs. IDNA |
|---|---|---|---|---|
| GNMX | Corgi Genomics & Precision Medicine ETF | 22.5% | -12 bp | -2.1% |
| GNOM | Global X Genomics & Biotechnology ETF | 19.9% | +3 bp | -1.2% |
| CANC | Tema Oncology ETF | 19.9% | +28 bp | -0.4% |
| WDNA | WisdomTree BioRevolution Fund | 19.4% | -2 bp | -1.2% |
| BBH | VanEck Biotech ETF | 19.2% | -12 bp | +6.2% |
| IBBQ | Invesco Nasdaq Biotechnology ETF | 18.2% | -28 bp | +1.7% |
| IBB | iShares Biotechnology ETF | 17.8% | -2 bp | +0.9% |
| BBP | Virtus LifeSci Biotech Products ETF | 17.5% | +32 bp | -2.1% |
| FTXH | First Trust Nasdaq Pharmaceuticals ETF | 16.1% | +13 bp | +8.5% |
| XBI | State Street SPDR S&P Biotech ETF | 15.5% | -12 bp | +1.3% |
Risk and Returns: IDNA vs. Comps (1 YR)
Notes: Top 10 overlapping ETFs. Funds with insufficient history not shown. Some funds may overlap. Hover over data point for ticker symbol.
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Results & Estimates (USD)
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | ||
|---|---|---|---|---|---|---|---|---|---|
| Sales per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Earnings per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Dividends per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- | ||
| Book value per share | -- | -- | -- | -- | -- | -- | -- | ||
| change (%) | -- | -- | -- | -- | -- | -- | -- |
Return on Equity
Net Margins
Content on this tab for Individual & Professional subscribers only. Start your FREE trial
Valuation Metrics
| Fwd Est | 2025 | 2026 | 2027 | |
| Price-to-sales | --x | --x | --x | --x |
| Price-to-earnings | --x | --x | --x | --x |
| Price-to-cash flow | --x | --x | --x | --x |
| Price-to-growth | --x | --x | --x | --x |
| Price-to-book value | --x | --x | --x | --x |
| Yield | --% | --% | --x | --% |
Based on closing prices from 7/15/2026
Peer Group Comparison
Sample data. Subscribe for access.
Historical Valuation Trends Sample data. Subscribe for access.
Notes: Based on adjusted historical results for current fund constituents. May differ from results achieved by past fund constituents. Max P/E of 100x.
Some content on this tab for Individual & Professional subscribers only. Start your FREE trial
ETF Research Center Rating
-1.5%
ALTAR SCORE™
1st
PERCENTILE
AVOID
ETFRC RATING
There are 733 funds in the Global Equity category with an average
ALTAR Score™ of 4.4% and a standard deviation
of 2.6%. IDNA's ALTAR Score™ is approximately -2.2 standard
deviations above the category average. This places IDNA in the 1st percentile
among funds in the category.
Sell-Side Consensus
$34.44
PRICE TARGET
+4.9%
UPSIDE